Influence of the safety and diagnostic accuracy of preoperative endoscopic ultrasound-guided fine-needle aspiration for resectable pancreatic cancer on clinical performance

Figure 5 Kaplan-Meier curves for relapse-free survival and overall survival in patients who did not receive adjuvant chemotherapy. A: Kaplan-Meier curves for relapse-free survival in patients who underwent resection for pancreatic cancer without adjuvant chemotherapy. The solid line indicates the Kaplan-Meyer curve for the FNA+ group and the dotted line represents that for the FNA- group. The median relapse-free survival time of the FNA+ and FNA- groups was 852 and 158 d, respectively (Log-rank test; P = 0.04); B: Kaplan-Meier curves for overall survival in patients who underwent resection for pancreatic cancer without adjuvant chemotherapy. The solid line indicates the Kaplan-Meyer curve for the FNA+ group and the dotted line represents that for the FNA- group. The median overall survival time of the FNA+ and FNA- groups was 829 and 400 d, respectively (Log-rank test; P = 0.08). FNA+: The group of patients who underwent endoscopic ultrasound-guided fine-needle aspiration before surgery; FNA-: The group of patients who did not undergo endoscopic ultrasound-guided fine-needle aspiration before surgery.